Dear Cheshire,
I don't have any hard evidence on which to base an opinion, but my instinct would be that your ME/CFS is due to a disturbance of B cells that has thrown up this monoclonal spike. It may not be this spike that is making you feel ill. I have previously seen a monoclonal spike associated with symptoms that got better with rituximab despite the spike staying the same. This may seem confusing but it was what I expected because in this case it was an IgM spike that did not fit for the symptoms. Our understanding of autoimmunity is that several B cell clones signal to each other and that the clones that keep an illness going are probably not the ones the actually cause the symptoms.
Monoclonal bands turn up quite often in autoimmune disease and it is hard to say whether they are from the cells that get things started or whether they are a spin off. What makes things difficult to interpret in an ME situation is that this is not (at least not yet) officially an autoimmune disease. So its all rather speculative.
Myeloma does not respond particularly well to rituximab in many cases because the myeloma cells have reached the plasma cell stage, which is no longer susceptible to rituximab (it has lost CD20). However, I have a myeloma patient who has done very well from the point of view of arthritis and monoclonal band with rituximab.
I guess that if I had very severe fatigue and a monoclonal band I would get one of my colleagues to give me rituximab - I would have to sign a piece of paper to say that all the consequences were my fault and pay for the infusion I guess, but I think I could swing it. But that is very different from recommending it to someone else. There are too many unknowns just at present, although this is changing quite fast.
One thing about the treatments used for true myeloma, like bortezomib and cytotoxics, is that they really only work on malignant cells that are out of control because of DNA translocations etc. If you have no evidence of such cells then maybe the cells making your band are benign cells that would be better targeted with something like rituximab, but I really couldn't say anything specific about that. The down side is that if the cells making the band are resistant to rituximab all the drug may do is get rid of useful B cells, leaving more room for the band to increase. I have not seen that happen, but this is a complicated situation.
Now that I am retired and no longer hold registration as a medical practitioner it would be wrong for me to give any formal advice on treatment. However, these would be my general thoughts.